Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov062019	Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting FT596 Selected by ASH for Feature at “CAR-T and Beyond” P ress Conference on December 7 Two Oral and Four Poster Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event at ASH on December 6 SAN DIEGO , Nov. Read All »	View HTML
Toggle SummaryJul172019	Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors SAN DIEGO , July 17, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Dr. Read All »	View HTML
Toggle SummaryMar182019	Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Karin Jooss , Ph.D. Read All »	View HTML
Toggle SummaryFeb202019	Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation SAN DIEGO , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Sarah Cooley , M.D., M.S., a leading expert in Read All »	View HTML
Toggle SummaryApr182019	Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development SAN DIEGO , April 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Yu-Waye (Wayne) Chu , M.D. Read All »	View HTML
Toggle SummaryDec102019	Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model Master Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus with No Evidence of Off-target Effects Read All »	View HTML
Toggle SummaryApr012019	Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting High-Throughput Selection of a Single Gene-Edited iPSC Enables Mass Production of Uniformly Engineered CAR T Cells FT819 Off-the-Shelf CAR19 T-cell Product Candidate Demonstrates Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus SAN DIEGO, Calif. Read All »	View HTML
Toggle SummaryMay072019	Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress First-ever Patient Treated in U.S. with an iPSC-derived Cell Therapy Successfully Advances through Six-dose Treatment Course No Dose-Limiting Toxicities or Serious Adverse Events Reported in Initial Cohort of FT500 iPSC-derived NK Cell Cancer Immunotherapy Patients FT500 Clinical Trial Now Open for Read All »	View HTML
Toggle SummaryMar052019	Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial Marks First-ever Human Administration of iPSC-derived Cell Therapy in the United States $201 Million in Cash & Short-term Investments as of December 31, 2018 SAN DIEGO , March 05, 2019 (GLOBE Read All »	View HTML
Toggle SummaryAug062019	Fate Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Operational Progress No FT500 DLTs Reported at Second Cell Dose Level in Monotherapy Arm or at First Cell Dose Level in Checkpoint Inhibitor Combination Arm in Solid Tumor Study Successfully Completed FT516 GMP Production and Product Release for Initiation of First-ever Clinical Trial of Engineered iPSC-derived Cell Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.